^
Association details:
| Biomarker: | CD74-ROS1 F2004L + PD-L1 expression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma
Published date:
02/08/2021
Excerpt:
A second NGS assay found a possible resistance mutation of c.6012T>G (p.F2004L)...nivolumab (200 mg, d1), nedaplatin (120 mg, d1), and pemetrexed (800 mg, d1) every 3 weeks were started to administered to the patient...The patient achieved a partial response to ICT...Unfortunately, it was not long before the disease progressed again...patients with PD-L1-positive ROS1-rearrangement NSCLC, and suggests that ICT might not be a better option than lorlatinib regimen in the second-line setting.
Secondary therapy:
pemetrexed + nedaplatin
DOI:
10.1136/jitc-2020-001967
